Disc Medicine Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 49.03% HC Wainwright & Co. $70 → $70 Reiterates Buy → Buy 06/17/2024 49.03% BMO Capital $50 → $

BenzingaJul 10 06:48 ET

H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70

H.C. Wainwright analyst Douglas Tsao maintains $Disc Medicine(IRON.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 39.0%

Moomoo NewsJul 10 06:31 ET · Ratings

Buy Rating Affirmed: Strong Phase 2 Results and Strategic FDA Engagement Bolster Confidence in Disc Medicine's Pipeline

TipRanksJul 10 06:15 ET

Disc Medicine(IRON.US) Director Sells US$9,253.3 in Common Stock

$Disc Medicine(IRON.US)$ Director White William Richard sold 201 shares of common stock on Jul 1, 2024 at an average price of $46.0363 for a total value of $9,253.3.Source: Announcement What is statem

Moomoo NewsJul 3 16:57 ET

Bitfarms Technologies, Vestis, and More Stocks See Action From Activist Investors -- Barrons.com

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen

Barron'sJun 28 20:11 ET

Disc Medicine Insider Bought Shares Worth $3,000,024, According to a Recent SEC Filing

Mona Ashiya, Director, on June 17, 2024, executed a purchase for 83,334 shares in Disc Medicine (IRON) for $3,000,024. Following the Form 4 filing with the SEC, Ashiya has control over a total of 235,

MT NewswiresJun 20 17:32 ET